Nattaporn Phanthaphol

2 Wanglang Road
Bangkok Noi, 10700, Thailand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Overcoming access barriers in European CAR-T therapy: the role of decentralized manufacturing and the EASYGEN framework.

Overcoming access barriers in European CAR-T therapy: the role of decentralized manufacturing and the EASYGEN framework.

Journal: Cytotherapy

Published: April 01, 2026

Next-generation of mesothelin-targeted CAR-T cells secreting anti-PD-L1 scFv for potent immunotherapy against 3D patient-derived colorectal cancer organoids.

Next-generation of mesothelin-targeted CAR-T cells secreting anti-PD-L1 scFv for potent immunotherapy against 3D patient-derived colorectal cancer organoids.

Journal: BMC medicine

Published: December 30, 2025

Next-generation CAR T cells targeting integrin αvβ6 and PD-L1 to enhance immunotherapy for cholangiocarcinoma.

Next-generation CAR T cells targeting integrin αvβ6 and PD-L1 to enhance immunotherapy for cholangiocarcinoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: October 02, 2025

Self-differentiated Dendritic Cells Presenting NY-ESO-1 Prime Cytotoxic T Cells for the Treatment of Multiple Myeloma.

Self-differentiated Dendritic Cells Presenting NY-ESO-1 Prime Cytotoxic T Cells for the Treatment of Multiple Myeloma.

Journal: Anticancer research

Published: September 05, 2025

Author Correction: Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.

Author Correction: Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.

Journal: Scientific reports

Published: February 06, 2025

Enhanced cytotoxicity against cholangiocarcinoma by fifth-generation chimeric antigen receptor T cells targeting integrin αvβ6 and secreting anti-PD-L1 scFv.

Enhanced cytotoxicity against cholangiocarcinoma by fifth-generation chimeric antigen receptor T cells targeting integrin αvβ6 and secreting anti-PD-L1 scFv.

Journal: Journal of translational medicine

Published: October 29, 2024

Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma.

Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: February 12, 2024

Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cells.

Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cells.

Journal: International immunopharmacology

Published: December 31, 2023

Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF dependent PDAC.

Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF dependent PDAC.

Journal: Scientific reports

Published: December 21, 2023

Cytotoxicity of fourth-generation anti-Trop2 CAR-T cells against breast cancer.

Cytotoxicity of fourth-generation anti-Trop2 CAR-T cells against breast cancer.

Journal: International immunopharmacology

Published: September 20, 2023

Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition.

Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition.

Journal: International immunopharmacology

Published: August 18, 2022

Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.

Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.

Journal: Scientific reports

Published: December 19, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026